The entire scintigraphy experiment was reviewed by Dr Aashish Gambhir for its results. While this data provided proof about the mechanism of action of SLIDD along with a drug of choice, the data generated from human clinical studies using Scintigraphy gamma imaging, provided substantial evidence about the SLIDD technology.

Budenoside-SLIDD formulation when given orally to human subjects, evidently established that the release of the drug in the colon was slow between 8 and 24 hours thus providing the necessary efficacy with minimal side-effects. The movement of Budenoside-SLIDD formulation down the entire GIT was monitored using high-end Scintigraphy.

Gamma imaging showing that 85% Budenoside release was found at the colon
Gamma imaging showing that 85% Budenoside release was found at the colon
Release of Budenoside indicating it is in its intact form & not denatured by gastric juices

It was clearly captured that there was 0% drug release found in upper part of GIT such as esophageal tract, stomach and small intestine. Scintigraphy images also revealed that the Esophageal transit time (ETT) for all participants was less than 5 seconds. For most subjects, the gastric emptying time was found to be 1 hour and the formulation was found to reach the ileocecal junction (Initial part of the colon) at 7hr. Budenoside formulated with SLIDD was able to deliver more than 95% the drug at the colon, the site of action.

Read more about SLIDD >> Commercial >> Science >> Scintigraphy